Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in ...

Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Martin ...

STAMFORD, Conn. - SpringWorks Therapeutics (SWTX), a healthcare company of Merck KGaA showing remarkable growth with a 730% revenue increase in the last twelve months, announced Tuesday that long-term ...

German Merck KGaA’s recently acquired subsidiary SpringWorks Therapeutics today announced that long-term efficacy and safety data from the Phase III DeFi trial of Ogsiveo (nirogacestat) were in the ...

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and ...

Discover how one of the biggest biopharma acquisitions of 2025 aims to expand rare tumor therapies for hard-to-treat cancers ...

SpringWorks Therapeutics Inc. shares SWTX were on track for a record percentage gain on Tuesday after the company got the first U.S. regulatory approval for a drug targeting a rare type of ...

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial In the phase III ...

Merck officially opened its €150m filtration manufacturing facility at Blarney Business Park in Cork last month. The Blarney facility is part of Merck’s largest life science investment to date in ...

GERMAN pharmaceuticals and technology company Merck KGaA slightly improved its midterm guidance for its health care business ahead of its capital markets day on Thursday.

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for desmoid tumours in Europe. Oral gamma secretase inhibitor Ogsiveo ...